BofA analyst Michael Ryskin raised the firm’s price target on Waters (WAT) to $375 from $370 and keeps a Neutral rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Waters Corporation Amends Credit Agreement for Flexibility
- Waters Corporation Re-elects Board at Annual Meeting
- Waters Corporation’s Strategic Acquisition of Halo Labs: Enhancing Biologics Capabilities and Market Position
- Waters acquires Halo Labs
- Waters price target raised to $370 from $350 at BofA